@article{1e9d23a6eb904fbea25f9c4743b96930,
title = "Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices",
abstract = "To determine real-world outcomes with first-line pembrolizumab monotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor expression ≥50%. Methods: This retrospective study included adults with ECOG 0-1 initiating first-line pembrolizumab monotherapy on/after 24 October 2016 (EHR cohort) or from 1 December 2016 through 30 November 2017 (spotlight cohort) with ≥6-month follow-up. We estimated Kaplan-Meier overall survival (OS, both cohorts), and, for spotlight, real-world progression-free survival (rwPFS) by Kaplan-Meier and real-world tumor response (rwTR). Results: For 423 patients in the EHR cohort and 188 in spotlight, median OS was 18.9 months (95% CI: 14.9-25.5) and 19.1 months (12.6-not reached), respectively. For spotlight, median rwPFS was 6.8 months (5.3-8.1); rwTR of complete/partial response was 48% (41-56%). Conclusion: Observed OS, rwPFS and rwTR were consistent with clinical trial findings.",
keywords = "PD-L1, antineoplastic agents, comparative effectiveness research, non-small-cell lung carcinoma, pembrolizumab, survival analysis",
author = "Vamsidhar Velcheti and Sheenu Chandwani and Xin Chen and Pietanza, {M. Catherine} and Bilal Piperdi and Thomas Burke",
note = "Funding Information: This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD). The funder of the study participated in development of the study design and funded the analysis of the data. All the authors, including those employed by MSD, participated in the data interpretation and writing of the manuscript. V Velcheti has served in an advisory and/or consultant role for Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, Celgene, Novartis, Amgen, Fulgent Genetics, Reddy Labs, Alkermes, Nektar Therapeutics, Novocure, and Foundation Medicine. S Chandwani, X Chen, MC Pietanza, B Piperdi and T Burke are full-time employees of MSD and own stock of Merck & Co., Inc., Kenilworth, NJ, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing and editorial assistance was provided by EV Hillyer, DVM. This assistance was funded by MSD. Publisher Copyright: {\textcopyright} 2019 {\textcopyright} 2019 Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.",
year = "2019",
doi = "10.2217/imt-2019-0177",
language = "English (US)",
volume = "11",
pages = "1541--1554",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "18",
}
